LOS ANGELES,Nov. 21,2024-- This holiday season,Yitahome invites you to redefine your space and make every moment count with #TheExtraordinaryWeeks campaign. From Thanksgiving to Christmas,enjoy aline-
Global Times: GCI promotes a natural feeling of affinity between Chinese and Latin American people
BEIJING,Nov. 21,2024-- In an era marked by unprecedented global transformations,the world stands at a critical crossroads,grappling with deepening deficits in peace,development,security,and governance
BuzzCast Short Video Contest Concludes Successfully, Honoring the Five Grand Winners
The factory building project of the second phase of Fujian Three Gorges Offshore Wind Power Industrial Park passed completion acceptance
Global Times: China's environmental protection efforts benefit whole Asia region
BEIJING,Nov. 19,2024-- China\'s continuous improvement of air quality and reduction of greenhouse gas emissions has benefited not only the country itself,but also the rest of Asia and the world,foreig
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development
BEIJING,Nov. 19,2024-- With the support of the RiDYMO® platform,we are able to comprehensively explore various potential targets in drug development,including protein-protein interactions,kinases,
The investment will initially focus on expediting development at existing sites inNavi Mumbai and Ambattur,Chennai,with an additional third site to be added in future.
Pop Culture Announces Improvement in Overall Operations During the Fiscal Year Ended June 30, 2024
XIAMEN,China,Nov. 19,2024-- In the fiscal year ended June 30,2024,POP CULTURE GROUP CO.,LTD. ("Pop Culture," or the "Company," Nasdaq: CPOP) continued to focus on its three busines
48-week end-of-treatment data from theongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα